DSS, Inc.'s Form 4 filing
Impact Biomedical Inc. (IBO) · filed Jan 6, 2026
- Accession no.
- 0001493152-26-000635
- Filed
- Jan 6, 2026
- Trade date
- May 22-27, 2025
- Filing delay
- 229 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $88.1K. It was filed 229 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| DSS, Inc.CIK 0000771999 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 22, 2025 | Common Stock | SSaleDisposed | −115,600 | $0.55 | −$63,580 | 590,424 | Direct | |
| May 27, 2025 | Common Stock | SSaleDisposed | −45,400 | $0.54 | −$24,516 | 545,024 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
This entity is a wholly-owned subsidiary of DSS, Inc. This amendment filing corrects an error in connection with the number of total shares of Common Stock that DSS, Inc. beneficially owns of IBO from its previously filed Form 4 on May 27, 2025. This corrected amendment includes DSS' correct beneficial ownership of IBO, which includes 545,024 shares of IBO's common stock pursuant to the Celios Asset sale.